Fed. Circ. OKs Hikma Gout Drug Sales In Takeda IP Case
The Federal Circuit on Wednesday released an opinion affirming a lower court's decision not to bar sales of Hikma Pharmaceuticals PLC's gout drug Mitigare, finding that Takeda Pharmaceuticals USA Inc. had...To view the full article, register now.
Already a subscriber? Click here to view full article